These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38752422)

  • 1. Legislating for Good Governance in the Pharmaceutical Sector through UN Convention Against Corruption (UNCAC) Compliance.
    Wong A; Perehudoff K; Kohler JC
    Glob Public Health; 2024 Jan; 19(1):2350649. PubMed ID: 38752422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk.
    Kohler JC; Dimancesco D
    Glob Health Action; 2020; 13(sup1):1694745. PubMed ID: 32194011
    [No Abstract]   [Full Text] [Related]  

  • 3. The influence of corruption and governance in the delivery of frontline health care services in the public sector: a scoping review of current and future prospects in low and middle-income countries of south and south-east Asia.
    Naher N; Hoque R; Hassan MS; Balabanova D; Adams AM; Ahmed SM
    BMC Public Health; 2020 Jun; 20(1):880. PubMed ID: 32513131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public sector reforms and their impact on the level of corruption: A systematic review.
    Mugellini G; Della Bella S; Colagrossi M; Isenring GL; Killias M
    Campbell Syst Rev; 2021 Jun; 17(2):e1173. PubMed ID: 37131927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disclosure, transparency, and accountability: a qualitative survey of public sector pharmaceutical committee conflict of interest policies in the World Health Organization South-East Asia Region.
    Grundy Q; Parker L; Wong A; Fusire T; Dimancesco D; Tisocki K; Walkowiak H; Vian T; Kohler J
    Global Health; 2022 Mar; 18(1):33. PubMed ID: 35303902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions to reduce corruption in the health sector.
    Gaitonde R; Oxman AD; Okebukola PO; Rada G
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008856. PubMed ID: 27528494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An interdisciplinary review of digital technologies to facilitate anti-corruption, transparency and accountability in medicines procurement.
    Mackey TK; Cuomo RE
    Glob Health Action; 2020; 13(sup1):1695241. PubMed ID: 32194014
    [No Abstract]   [Full Text] [Related]  

  • 8. Exploring anti-corruption, transparency, and accountability in the World Health Organization, the United Nations Development Programme, the World Bank Group, and the Global Fund to Fight AIDS, Tuberculosis and Malaria.
    Kohler JC; Bowra A
    Global Health; 2020 Oct; 16(1):101. PubMed ID: 33081805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sustainable development goals as a framework to combat health-sector corruption.
    Mackey TK; Vian T; Kohler J
    Bull World Health Organ; 2018 Sep; 96(9):634-643. PubMed ID: 30262945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tackling corruption in the pharmaceutical systems worldwide with courage and conviction.
    Cohen JC; Mrazek M; Hawkins L
    Clin Pharmacol Ther; 2007 Mar; 81(3):445-9. PubMed ID: 17251983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing transparency and accountability in national pharmaceutical systems.
    Paschke A; Dimancesco D; Vian T; Kohler JC; Forte G
    Bull World Health Organ; 2018 Nov; 96(11):782-791. PubMed ID: 30455533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-corruption, transparency and accountability in health: concepts, frameworks, and approaches.
    Vian T
    Glob Health Action; 2020; 13(sup1):1694744. PubMed ID: 32194010
    [No Abstract]   [Full Text] [Related]  

  • 13. Exploring corruption in the South African health sector.
    Rispel LC; de Jager P; Fonn S
    Health Policy Plan; 2016 Mar; 31(2):239-49. PubMed ID: 26104821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opening the Policy Window to Mobilize Action Against Corruption in the Health Sector Comment on "We Need to Talk About Corruption in Health Systems".
    Mackey TK
    Int J Health Policy Manag; 2019 Nov; 8(11):668-671. PubMed ID: 31779293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoting anti-corruption, transparency and accountability in the recruitment and promotion of health workers to safeguard health outcomes.
    Kirya MT
    Glob Health Action; 2020; 13(sup1):1701326. PubMed ID: 32194012
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-corruption, Transparency and Accountability: Case Study of Healthcare in the Arab Countries.
    Hunter M; Uwaydah Mardini R; El-Seblani A; Elsayed S
    Glob Health Action; 2020; 13(sup1):1704529. PubMed ID: 32194015
    [No Abstract]   [Full Text] [Related]  

  • 17. A systematic review of digital technology and innovation and its potential to address anti-corruption, transparency, and accountability in the pharmaceutical supply chain.
    Saeed G; Kohler JC; Cuomo RE; Mackey TK
    Expert Opin Drug Saf; 2022 Aug; 21(8):1061-1088. PubMed ID: 35714366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of corruption in the health sector: theory, methods and interventions.
    Vian T
    Health Policy Plan; 2008 Mar; 23(2):83-94. PubMed ID: 18281310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?
    Vogler S; Salcher-Konrad M; Habimana K
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):867-878. PubMed ID: 37450611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Good governance and corruption in the health sector: lessons from the Karnataka experience.
    Huss R; Green A; Sudarshan H; Karpagam S; Ramani K; Tomson G; Gerein N
    Health Policy Plan; 2011 Nov; 26(6):471-84. PubMed ID: 21169338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.